Locally Recurrent and Metastatic Breast Cancer
Conditions
Keywords
Clinical trial, AMG 706, Anti-angiogenesis, Locally Recurrent, Metastatic, Breast Cancer, VEGF, Angiogenesis Inhibitor, Oral, Multi-kinase Inhibitor, Anti-tumor, PDGF receptor, Paclitaxel, Docetaxel, Targeted Therapy, Oncology, Amgen, c-Kit
Brief summary
This open-label, dose-finding, multi-center study is designed to determine the safety and the maximum tolerated dose of AMG 706 given once daily in combination with either weekly paclitaxel (Arm A) or once-every-3 week docetaxel (Arm B) in subjects with locally recurrent or metastatic breast cancer. Secondarily, this study will evaluate the pharmacokinetic (PK) profile of AMG 706 in both treatment arms, the PK profile of paclitaxel in Arm A and the PK profile of docetaxel in Arm B. Additionally, this study will assess objective tumor response and duration of response. Exploratory endpoints include the investigation of potential biomarker development and to assess the effects of genetic variation in drug metabolism genes, cancer genes and drug target genes on subject response to AMG 706 in combination with paclitaxel or docetaxel.
Interventions
DRUGDocetaxel
Subjects assigned to Arm B, cohorts will receive 75 or 100 mg/m2 of docetaxel (based on cohort assignment) on Day 1 repeated every 21 days (1 cycle). AMG 706 will be administered concurrently on Days 3-21 of Cycle 1, and Days 1-21 of Cycle 2 and beyond.
DRUGPaclitaxel
Subjects assigned to Arm A will receive 90 mg/m2 of paclitaxel on Days 1, 8 and 15 repeated every 28 days (1 cycle). On Arm A, AMG 706 will be concurrently administered on Days 3-28 of Cycle 1, and Days 1-28 of Cycle 2 and beyond.
DRUGAMG 706
Subjects assigned to Arm A will receive AMG 706 at 50, 75, 100 or 125 mg daily (based on cohort assignment) on Days 3-28 of Cycle 1, and Days 1-28 of Cycle 2 and beyond in combination wth paclitaxel 90 mg/m2. Paclitaxel will be administered on Days 1, 8 and 15 every 28 days. Subjects assigned to Arm B will receive AMG 706 at 50, 75, 100 or 125 mg daily(based on cohort assignment) on Days 3-21 of Cycle 1, and Days 1-21 of Cycle 2 and beyond in combination with docetaxel. Docetaxel will be administered at either 75 mg/m2 or 100 mg/m2 on Day 1 every 21 days.
Sponsors
Amgen
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically or cytologically confirmed adenocarcinoma of the breast with locally recurrent or metastatic disease. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Female 18 years of age or older. * Adequate hematologic, renal and hepatic function. * Competent to comprehend, sign, and date an IRB-approved informed consent form. * Subjects of childbearing potential and sexually active must provide a negative pregnancy test and use accepted and effective method of contraception.
Exclusion criteria
* Prior taxane-containing treatment within 6 months prior to enrollment. * Prior treatment including chemotherapy and/or endocrine therapy discontinued \< 21 days prior to enrollment. * More than one prior systemic chemotherapy for locally recurrent or metastatic breast cancer. * Current or prior history of central nervous system metastases. * History of arterial or venous thrombosis within 1 year prior to enrollment. * History of bleeding diathesis or bleeding within 14 days prior to enrollment. * Radiation therapy to a significant portion of bone marrow or prior history of high-dose chemotherapy requiring bone marrow or stem cell support. * Hypersensitivity to paclitaxel, docetaxel, or drugs using the vehicle cremophor. * Prior VEGFr targeted therapies within 30 days of enrollment. * Any anticoagulant therapy within 7 days prior to enrollment, except for warfarin of less than 2mg per day. * Clinically significant cardiac disease including myocardial infarction or other cardiovascular related event within 1 year before enrollment. * Uncontrolled hypertension (systolic \>150 mmHg; diastolic \> 90 mmHg). * Known HIV positive, hepatitis C positive or hepatitis B surface antigen positive. * Prior bevacizumab or trastuzumab therapy within 12 weeks of enrollment. * Non-healing wound, ulcer or fracture. * Known history of prior episodes of cholecystitis, prior biliary procedure or prior or ongoing biliary disease. * Unable to take oral medications. * Not recovered from previous therapies. * Major surgery within 28 days prior to enrollment. * Prior malignancy unless treated with curative intent and without evidence of disease for greater than 3 years before enrollment. * Peripheral neuropathy grade \> 1 per CTCAE version 3.0
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of dose limiting toxicities (DLTs) | Cycle 1 of treatment. For Arm A, 1 cycle = 28 days. For Arm B, 1 cycle = 21 days |
Secondary
| Measure | Time frame |
|---|---|
| Pharmacokinetics of AMG 706 when administered with paclitaxel (Arm A) or docetaxel (Arm B) | Cycle 1 (Arms A and B) and Cycle 2 Arm B only) |
| Pharmacokinetics of paclitaxel (Arm A) when administered with AMG 706 | Cycle 1, D1 and D8 for subjects in Arm A only |
| Pharmacokinetics of docetaxel (Arm B) when administered with AMG 706 | Cycles 1 and 2 for subjects in Arm B only |
| Objective tumor response (complete or partial response) according to modified RECIST | Subjects in Arm A: every 8 weeks until discontuation. Subjects in Arm B:every 6 weeks until discontinuation. |
| Duration of response (calculated for those subjects who respond): time from first objective tumor response to objective disease progression or death. | Subjects in Arm A: every 8 weeks until discontuation. Subjects in Arm B:every 6 weeks until discontinuation. |
| Incidence of adverse events and clinical laboratory abnormalities not defined as DLTs | From study entry through 30 days post discontinuation of study treatment |
Outcome results
None listed